VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

New method of delivering growth factors could lead to revolutionary heart treatment

Ever since the Nobel Prize for nerve growth factor was awarded more than 30 years ago, researchers have been searching for ways to use growth factor clinically.

3 Aug 2011

Novel therapy reduces elevated blood levels of toxic protein in women with preeclampsia

A novel therapy that reduces elevated blood levels of a potentially toxic protein in women with preeclampsia, a dangerous complication of pregnancy, may someday address the therapeutic dilemma posed by the condition - balancing life-threatening risks to the mother with the dangers that early delivery poses to an immature fetus.

3 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

Receptor GPR56 could have a critical role in cancer progression

Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors.

21 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Study shows effect of maternal height on multiple implantation

The researchers say that this is the first time the effect of maternal height on multiple implantation has been shown.

4 Jul 2011

MGH researchers discover new plant compounds that block blood vessel growth

Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs - agents that interfere with the development of blood vessels.

2 Jul 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Key molecule of vascular system directs axons during neural circuit formation

Dr. Fr-d-ric Charron, researcher at the Institut de recherches cliniques de Montr-al (IRCM), and his team have shown for the first time that a key molecule of the vascular system directs axons during the formation of neural circuits.

9 Jun 2011

Researchers identify key molecule responsible for breast tumor metastasis

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified a key player in the spread of breast cancer. The findings, published today in the online edition of Nature, identify a critical molecule that helps cancer spread beyond the primary tumor.

9 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

7 Jun 2011

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

VEGF News and Research

Further Reading

New method of delivering growth factors could lead to revolutionary heart treatment

Novel therapy reduces elevated blood levels of toxic protein in women with preeclampsia

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Receptor GPR56 could have a critical role in cancer progression

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Study shows effect of maternal height on multiple implantation

MGH researchers discover new plant compounds that block blood vessel growth

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

NASDAQ halts Regeneron's common stock

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Key molecule of vascular system directs axons during neural circuit formation

Researchers identify key molecule responsible for breast tumor metastasis

NYU Cancer Institute scientists present new research findings at ASCO 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Scientists discover key molecule that targets tumour blood vessels

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo